BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia

Journal of Molecular Diagnostics

Volumn 15, Issue 5, 2013, Pages 565-576

  Press, Richard D ^a   Kamel Reid, Suzanne ^b   Ang, Daphne ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PONATINIB;

CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DIAGNOSTIC ACCURACY; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE MUTATION; HUMAN; MALIGNANT TRANSFORMATION; MOLECULAR DIAGNOSTICS; MUTATIONAL ANALYSIS; PATIENT MONITORING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84882269182     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2013.04.007     Document Type: Review

References (65)

1. P.C. Nowell, and D.A. Hungerford Chromosome studies on normal and leukemic human leukocytes J Natl Cancer Inst 25 1960 85 109
2. J.D. Rowley Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining Nature 243 1973 290 293
3. S.D. Horne, J.B. Stevens, B.Y. Abdallah, G. Liu, S.W. Bremer, C.J. Ye, and H.H. Heng Why imatinib remains an exception of cancer research J Cell Physiol 228 2012 665 670
4. M. Bjorkholm, L. Ohm, S. Eloranta, A. Derolf, M. Hultcrantz, J. Sjoberg, T. Andersson, M. Hoglund, J. Richter, O. Landgren, S.Y. Kristinsson, and P.W. Dickman Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008 J Clin Oncol 29 2011 2514 2520
5. R. Hehlmann How I treat CML blast crisis Blood 120 2012 737 747
6. H. Kantarjian, S. O'Brien, E. Jabbour, G. Garcia-Manero, A. Quintas-Cardama, J. Shan, M.B. Rios, F. Ravandi, S. Faderl, T. Kadia, G. Borthakur, X. Huang, R. Champlin, M. Talpaz, and J. Cortes Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience Blood 119 2012 1981 1987
7. B.J. Druker, F. Guilhot, S.G. O'Brien, I. Gathmann, H. Kantarjian, N. Gattermann, M.W. Deininger, R.T. Silver, J.M. Goldman, R.M. Stone, F. Cervantes, A. Hochhaus, B.L. Powell, J.L. Gabrilove, P. Rousselot, J. Reiffers, J.J. Cornelissen, T. Hughes, H. Agis, T. Fischer, G. Verhoef, J. Shepherd, G. Saglio, A. Gratwohl, J.L. Nielsen, J.P. Radich, B. Simonsson, K. Taylor, M. Baccarani, C. So, L. Letvak, and R.A. Larson Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2006 2408 2417
8. M. Deininger, S.G. O'Brien, F. Guilhot, J.M. Goldman, A. Hochhaus, T.P. Hughes, J.P. Radich, A.K. Hatfield, M. Mone, J. Filian, J. Reynolds, I. Gathmann, R.A. Larson, and B.J. Druker International randomized study of interferon versus STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (abstract) Blood (ASH Annual Meeting Abstracts) 114 2009 Abstract 1126
9. M. Agrawal, R.J. Garg, J. Cortes, and A. Quintas-Cardama Tyrosine kinase inhibitors: the first decade Curr Hematol Malig Rep 5 2010 70 80
10. J.M. Diamond, and J.V. Melo Mechanisms of resistance to BCR-ABL kinase inhibitors Leuk Lymphoma 52 Suppl 1 2011 12 22
11. D. Jones, S. Kamel-Reid, D. Bahler, H. Dong, K. Elenitoba-Johnson, R. Press, N. Quigley, P. Rothberg, D. Sabath, D. Viswanatha, K. Weck, and J. Zehnder Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology J Mol Diagn 11 2009 4 11
12. S. Soverini, A. Hochhaus, F.E. Nicolini, F. Gruber, T. Lange, G. Saglio, F. Pane, M.C. Muller, T. Ernst, G. Rosti, K. Porkka, M. Baccarani, N.C. Cross, and G. Martinelli BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet Blood 118 2011 1208 1215
13. G. Saglio, D.W. Kim, S. Issaragrisil, P. le Coutre, G. Etienne, C. Lobo, R. Pasquini, R.E. Clark, A. Hochhaus, T.P. Hughes, N. Gallagher, A. Hoenekopp, M. Dong, A. Haque, R.A. Larson, and H.M. Kantarjian Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia N Engl J Med 362 2010 2251 2259
14. H. Kantarjian, N.P. Shah, A. Hochhaus, J. Cortes, S. Shah, M. Ayala, B. Moiraghi, Z. Shen, J. Mayer, R. Pasquini, H. Nakamae, F. Huguet, C. Boque, C. Chuah, E. Bleickardt, M.B. Bradley-Garelik, C. Zhu, T. Szatrowski, D. Shapiro, and M. Baccarani Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 362 2010 2260 2270
15. H.M. Kantarjian, A. Hochhaus, G. Saglio, F.P. De Souza Santos, I.W. Flinn, L. Stenke, Y.-T. Goh, G. Rosti, H. Nakamae, N.J. Gallagher, A. Hoenekopp, R. Blakesley, R.A. Larson, and T.P. Hughes Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase. Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial Lancet Oncol 12 2011 841 851
16. A. Hochhaus, N.P. Shah, J.E. Cortes, M. Baccarani, M.B. Bradley-Garelik, D. Dejardin, and H. Kantarjian Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up J Clin Oncol 30 2012 6504
17. R.A. Larson, A. Hochhaus, T.P. Hughes, R.E. Clark, G. Etienne, D.W. Kim, I.W. Flinn, M. Kurokawa, B. Moiraghi, R. Yu, R.E. Blakesley, N.J. Gallagher, G. Saglio, and H.M. Kantarjian Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up Leukemia 26 2012 2197 2203
18. J.E. Cortes, H.M. Kantarjian, T.H. Brümmendorf, D.W. Kim, A.G. Turkina, Z.X. Shen, R. Pasquini, H.J. Khoury, S. Arkin, A. Volkert, N. Besson, R. Abbas, J. Wang, E. Leip, and C. Gambacorti-Passerini Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib Blood 118 2011 4567 4576
19. J.E. Cortes, H. Kantarjian, N.P. Shah, D. Bixby, M.J. Mauro, I. Flinn, T. O'Hare, S. Hu, N.I. Narasimhan, V.M. Rivera, T. Clackson, C.D. Turner, F.G. Haluska, B.J. Druker, M.W. Deininger, and M. Talpaz Ponatinib in refractory Philadelphia chromosome-positive leukemias N Engl J Med 367 2012 2075 2088
20. M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, A. Gratwohl, F. Guilhot, M. Horowitz, T. Hughes, H. Kantarjian, R. Larson, D. Niederwieser, R. Silver, and R. Hehlmann Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood 108 2006 1809 1820
21. T. Hughes, M. Deininger, A. Hochhaus, S. Branford, J. Radich, J. Kaeda, M. Baccarani, J. Cortes, N.C. Cross, B.J. Druker, J. Gabert, D. Grimwade, R. Hehlmann, S. Kamel-Reid, J.H. Lipton, J. Longtine, G. Martinelli, G. Saglio, S. Soverini, W. Stock, and J.M. Goldman Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood 108 2006 28 37
22. S. Branford, T.P. Hughes, and Z. Rudzki Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics Br J Haematol 107 1999 587 599
23. R. Hehlmann, M. Lauseker, S. Jung-Munkwitz, A. Leitner, M.C. Muller, N. Pletsch, U. Proetel, C. Haferlach, B. Schlegelberger, L. Balleisen, M. Hanel, M. Pfirrmann, S.W. Krause, C. Nerl, H. Pralle, A. Gratwohl, D.K. Hossfeld, J. Hasford, A. Hochhaus, and S. Saussele Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia J Clin Oncol 29 2011 1634 1642
24. T.P. Hughes, A. Hochhaus, S. Branford, M.C. Muller, J.S. Kaeda, L. Foroni, B.J. Druker, F. Guilhot, R.A. Larson, S.G. O'Brien, M.S. Rudoltz, M. Mone, E. Wehrle, V. Modur, J.M. Goldman, and J.P. Radich Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon versus STI571 (IRIS) Blood 116 2010 3758 3765
25. R.D. Press, Z. Love, A.A. Tronnes, R. Yang, T. Tran, S. Mongoue-Tchokote, M. Mori, M.J. Mauro, M.W. Deininger, and B.J. Druker BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML Blood 107 2006 4250 4256
26. N.C. Cross Standardisation of molecular monitoring for chronic myeloid leukaemia Best Pract Res Clin Haematol 22 2009 355 365
27. M. Baccarani, J. Cortes, F. Pane, D. Niederwieser, G. Saglio, J. Apperley, F. Cervantes, M. Deininger, A. Gratwohl, F. Guilhot, A. Hochhaus, M. Horowitz, T. Hughes, H. Kantarjian, R. Larson, J. Radich, B. Simonsson, R.T. Silver, J. Goldman, and R. Hehlmann Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet J Clin Oncol 27 2009 6041 6051
28. S. Faderl, M. Talpaz, Z. Estrov, and H.M. Kantarjian Chronic myelogenous leukemia: biology and therapy Ann Intern Med 131 1999 207 219
29. H. Kantarjian, C. Sawyers, A. Hochhaus, F. Guilhot, C. Schiffer, C. Gambacorti-Passerini, D. Niederwieser, D. Resta, R. Capdeville, U. Zoellner, M. Talpaz, B. Druker, J. Goldman, S.G. O'Brien, N. Russell, T. Fischer, O. Ottmann, P. Cony-Makhoul, T. Facon, R. Stone, C. Miller, M. Tallman, R. Brown, M. Schuster, T. Loughran, A. Gratwohl, F. Mandelli, G. Saglio, M. Lazzarino, D. Russo, M. Baccarani, and E. Morra Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Engl J Med 346 2002 645 652
30. L.P. Akard, and Y.L. Wang Translating trial-based molecular monitoring into clinical practice: importance of international standards and practical considerations for community practitioners Clin Lymphoma Myeloma Leuk 11 2011 385 395
31. S. Branford, L. Fletcher, N.C. Cross, M.C. Muller, A. Hochhaus, D.W. Kim, J.P. Radich, G. Saglio, F. Pane, S. Kamel-Reid, Y.L. Wang, R.D. Press, K. Lynch, Z. Rudzki, J.M. Goldman, and T. Hughes Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials Blood 112 2008 3330 3338
32. T.P. Hughes, J. Kaeda, S. Branford, Z. Rudzki, A. Hochhaus, M.L. Hensley, I. Gathmann, A.E. Bolton, I.C. van Hoomissen, J.M. Goldman, and J.P. Radich Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med 349 2003 1423 1432
33. Baccarani M, Deininger M, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes T, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Muller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Sauβele S, Schiffer C, Silver R, Simonsson B, Steegmann J-L, Golman JM, Hehlmann R: European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood http://dx.doi.org/10.1182/blood-2013-05-501569
34. B. Hanfstein, M.C. Muller, R. Hehlmann, P. Erben, M. Lauseker, A. Fabarius, S. Schnittger, C. Haferlach, G. Gohring, U. Proetel, H.J. Kolb, S.W. Krause, W.K. Hofmann, J. Schubert, H. Einsele, J. Dengler, M. Hanel, C. Falge, L. Kanz, A. Neubauer, M. Kneba, F. Stegelmann, M. Pfreundschuh, C.F. Waller, S. Branford, T.P. Hughes, K. Spiekermann, G.M. Baerlocher, M. Pfirrmann, J. Hasford, S. Saussele, and A. Hochhaus Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) Leukemia 26 2012 2096 2102
35. D. Marin, A.R. Ibrahim, C. Lucas, G. Gerrard, L. Wang, R.M. Szydlo, R.E. Clark, J.F. Apperley, D. Milojkovic, M. Bua, J. Pavlu, C. Paliompeis, A. Reid, K. Rezvani, J.M. Goldman, and L. Foroni Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors J Clin Oncol 30 2012 232 238
36. Hochhaus A, Guilhot F, Kathrin Haifa AA, Rosti G, Nakaseko C, De Souza CA, Larson R, Kantry HM, Hoenekopp A, Blakesley R, Yu R, Saglio G, Hughes T. Early BCR-ABL transcript levels predict future molecular response and long-term outcomes in newly diagnosed patients with chronic myeloid leukemia in chronic phase: analysis of ENESTnd 3-year data. 17th Congress of the European Hematology Association, 2012 June 15-17, Amsterdam, The Netherlands, Abstract 0584
37. S. Branford, D.-W. Kim, S. Soverini, E. Gottardi, L. Beppu, M.C. Muller, A. Haque, Y. Shou, R.C. Woodman, H.M. Kantarjian, G. Martinelli, J.P. Radich, G. Saglio, T.P. Hughes, and A. Hochhaus Molecular response at 3 months on nilotinib therapy predicts response and long-term outcomes in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) (abstract) Blood (ASH Annual Meeting Abstracts) 114 2009 3292
38. N.C. Cross, H.E. White, M.C. Muller, G. Saglio, and A. Hochhaus Standardized definitions of molecular response in chronic myeloid leukemia Leukemia 26 2012 2172 2175
39. R.D. Press, C. Galderisi, R. Yang, C. Rempfer, S.G. Willis, M.J. Mauro, B.J. Druker, and M.W. Deininger A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response Clin Cancer Res 13 2007 6136 6143
40. S. Branford, J.F. Seymour, A. Grigg, C. Arthur, Z. Rudzki, K. Lynch, and T. Hughes BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria Clin Cancer Res 13 2007 7080 7085
41. F.X. Mahon, D. Rea, J. Guilhot, F. Guilhot, F. Huguet, F. Nicolini, L. Legros, A. Charbonnier, A. Guerci, B. Varet, G. Etienne, J. Reiffers, and P. Rousselot Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial Lancet Oncol 11 2010 1029 1035
42. M. Breccia, and G. Alimena The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era Crit Rev Oncol Hematol 79 2011 135 143
43. R.D. Press, S.G. Willis, J. Laudadio, M.J. Mauro, and M.W. Deininger Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib Blood 114 2009 2598 2605
44. D. Marin, A. Bazeos, F.X. Mahon, L. Eliasson, D. Milojkovic, M. Bua, J.F. Apperley, R. Szydlo, R. Desai, K. Kozlowski, C. Paliompeis, V. Latham, L. Foroni, M. Molimard, A. Reid, K. Rezvani, H. de Lavallade, C. Guallar, J. Goldman, and J.S. Khorashad Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib J Clin Oncol 28 2010 2381 2388
45. H.M. Kantarjian, J. Shan, D. Jones, S. O'Brien, M.B. Rios, E. Jabbour, and J. Cortes Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response J Clin Oncol 27 2009 3659 3663
46. J.S. Khorashad, H. deLavallade, J.F. Apperley, D. Milojkovic, A.G. Reid, M. Bua, R. Szydlo, E. Olavarria, J. Kaeda, J.M. Goldman, and D. Marin Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression J Clin Oncol 26 2008 4806 4813
47. S. Branford, Z. Rudzki, I. Parkinson, A. Grigg, K. Taylor, J.F. Seymour, S. Durrant, P. Browett, A.P. Schwarer, C. Arthur, J. Catalano, M.F. Leahy, R. Filshie, K. Bradstock, R. Herrmann, D. Joske, K. Lynch, and T. Hughes Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations Blood 104 2004 2926 2932
48. T. Terasawa, I. Dahabreh, and T.A. Trikalinos BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia PLoS Curr 2 2010 RRN1204
49. S. Branford, J.V. Melo, and T.P. Hughes Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 114 2009 5426 5435
50. T. O'Hare, C.A. Eide, and M.W. Deininger Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Blood 110 2007 2242 2249
51. T. O'Hare, W.C. Shakespeare, X. Zhu, C.A. Eide, V.M. Rivera, F. Wang, L.T. Adrian, T. Zhou, W.S. Huang, Q. Xu, C.A. Metcalf 3rd, J.W. Tyner, M.M. Loriaux, A.S. Corbin, S. Wardwell, Y. Ning, J.A. Keats, Y. Wang, R. Sundaramoorthi, M. Thomas, D. Zhou, J. Snodgrass, L. Commodore, T.K. Sawyer, D.C. Dalgarno, M.W. Deininger, B.J. Druker, and T. Clackson AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance Cancer Cell 16 2009 401 412
52. S. Redaelli, R. Piazza, R. Rostagno, V. Magistroni, P. Perini, M. Marega, C. Gambacorti-Passerini, and F. Boschelli Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants J Clin Oncol 27 2009 469 471
53. D.W. Sherbenou, O. Hantschel, L. Turaga, I. Kaupe, S. Willis, T. Bumm, R.D. Press, G. Superti-Furga, B.J. Druker, and M.W. Deininger Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia Leukemia 22 2008 1184 1190
54. F.X. Gruber, H. Hjorth-Hansen, I. Mikkola, L. Stenke, and T. Johansen A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib Leukemia 20 2006 2057 2060
55. J. Laudadio, M.W. Deininger, M.J. Mauro, B.J. Druker, and R.D. Press An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy J Mol Diagn 10 2008 177 180
56. T. O'Hare, M.S. Zabriskie, C.A. Eide, A. Agarwal, L.T. Adrian, H. You, A.S. Corbin, F. Yang, R.D. Press, V.M. Rivera, J. Toplin, S. Wong, M.W. Deininger, and B.J. Druker The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia Blood 118 2011 5250 5254
57. T.P. Hughes, and S. Branford Monitoring disease response to tyrosine kinase inhibitor therapy in CML Hematology Am Soc Hematol Educ Program 2009 477 487
58. T. Zhang, S. Grenier, B. Nwachukwu, C. Wei, J.H. Lipton, and S. Kamel-Reid Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations J Mol Diagn 9 2007 421 430
59. E. Beillard, N. Pallisgaard, V.H. van der Velden, W. Bi, R. Dee, E. van der Schoot, E. Delabesse, E. Macintyre, E. Gottardi, G. Saglio, F. Watzinger, T. Lion, J.J. van Dongen, P. Hokland, and J. Gabert Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe Against Cancer program Leukemia 17 2003 2474 2486
60. M.C. Muller, P. Erben, G. Saglio, E. Gottardi, C.G. Nyvold, T. Schenk, T. Ernst, S. Lauber, J. Kruth, R. Hehlmann, and A. Hochhaus Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories Leukemia 22 2008 96 102
61. M.C. Muller, G. Saglio, F. Lin, H. Pfeifer, R.D. Press, R.R. Tubbs, P. Paschka, E. Gottardi, S.G. O'Brien, O.G. Ottmann, H. Stockinger, L. Wieczorek, K. Merx, H. Konig, U. Schwindel, R. Hehlmann, and A. Hochhaus An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR Haematologica 92 2007 970 973
62. M.F. Yamada, T. Fujiwara, I. Ishikawa, K. Kohata, C. Katoh, K. Miyamura, and H. Harigae Interlaboratory comparison of quantitative RT-PCR based detection for minimal residual disease in leukemias: a standardization approach in Japan Tohoku J Exp Med 214 2008 97 104
63. Y.L. Wang, J.W. Lee, E. Cesarman, D.K. Jin, and B. Csernus Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts J Mol Diagn 8 2006 231 239
64. J.W. Lee, Q. Chen, D.M. Knowles, E. Cesarman, and Y.L. Wang beta-Glucuronidase is an optimal normalization control gene for molecular monitoring of chronic myelogenous leukemia J Mol Diagn 8 2006 385 389
65. H.E. White, P. Matejtschuk, P. Rigsby, J. Gabert, F. Lin, Y. Lynn Wang, S. Branford, M.C. Muller, N. Beaufils, E. Beillard, D. Colomer, D. Dvorakova, H. Ehrencrona, H.G. Goh, H. El Housni, D. Jones, V. Kairisto, S. Kamel-Reid, D.W. Kim, S. Langabeer, E.S. Ma, R.D. Press, G. Romeo, L. Wang, K. Zoi, T. Hughes, G. Saglio, A. Hochhaus, J.M. Goldman, P. Metcalfe, and N.C. Cross Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA Blood 116 2010 e111 e117